1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Facility Inspection Leads To FDA Warning For iRhythm

 
• By Brian Bossetta

The US FDA issued a warning letter to iRhythm Technologies related to its Zio cardiac monitor system after an August 2022 inspection of the firm’s California facility. Wells Fargo predicts little impact on the company.

Warning
• Source: Shutterstock

The Food and Drug Administration sent iRhythm Technologies a warning letter on 25 May alleging “non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Zio AT System and medical device quality system requirements” according to an 8-K report the company filed with the US Securities and Exchange Commission (SEC).

The FDA’s letter resulted from an inspection of the company’s facility located in Cypress, CA that concluded last August, though...

More from Regulation

More from Policy & Regulation

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.